Sirtratumab vedotin Antibody
Sirtratumab vedotin (ASG15-ME) is an antibody-drug conjugate (ADC) targeting SLITRK6, which delivers the cytotoxic agent MMAE via a cleavable linker. This ADC is utilized in cancer research, particularly for investigating targeted therapies in preclinical in vitro and in vivo models of SLITRK6-expressing tumors.
Product Specifications
Target
Antibody-Drug Conjugates (ADCs)
Conjugation
Unconjugated
Concentration
2.57 mg/mL
Purity
95.00% (May vary between batches)
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
PC1019479-01 250 mg
1- (3- (benzyloxy) -6-bromo-2-fluorophenyl) -2-fluoroethanone
Sign In for Pricing
View Details PC1019479-02 500 mg
1- (3- (benzyloxy) -6-bromo-2-fluorophenyl) -2-fluoroethanone
Sign In for Pricing
View Details PC1019479-03 1 g
1- (3- (benzyloxy) -6-bromo-2-fluorophenyl) -2-fluoroethanone
Sign In for Pricing
View Details G7002 96 Tests
Regenerating islet-derived protein 3-α (REG3A) Mouse ELISA Kit
Sign In for Pricing
View Details 
